NurExone Biologic Secures FDA Orphan-Drug Designation to Expedite Development of ExoPTEN Therapy for Treating Acute Spinal Cord Injuries

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a leading biotechnology company, is delighted to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its innovative therapy, ExoPTEN. This designation recognizes the therapeutic potential of ExoPTEN for acute spinal cord injury, a condition with limited treatment options.

Orphan drug designation provides valuable benefits to pharmaceutical companies working on treatments for rare diseases, which are defined as those affecting fewer than 200,000 people in the United States. These benefits encompass market exclusivity, financial incentives, regulatory support, and assistance in the drug development process. Overall, this designation encourages and supports the development of specific therapies, ultimately increasing access to treatments for patients.

Securing orphan-drug designation is a significant achievement for NurExone. This designation pertains to the use of small extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) loaded with short and modified interfering RNA (siRNA) targeting the phosphatase and tensin homolog (PTEN) protein for the treatment of acute spinal cord injury, as incorporated in NurExone's ExoPTEN drug, which is currently in development.

"Obtaining orphan-drug designation is expected to simplify our path to market, shorten the regulatory process, resulting in substantial cost savings for the company, and grant valuable market exclusivity. We are grateful for the official recognition of the potential impact of our therapy on the lives of patients coping with acute spinal cord injuries," stated Dr. Shaltiel, CEO of NurExone Biologic, Ltd.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!